Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Apr
10
2023
Plaintiffs Argue There is No Evidence FDA Will Act Soon on “Natural” Definition Keller and Heckman LLP
Apr
10
2023
What FQHCs Need to Know About Telehealth After the PHE Foley & Lardner LLP
Apr
8
2023
Statement from Attorney General Merrick B. Garland The U.S. Department of Justice
Apr
7
2023
Texas Lab Settles Unnecessary Drug Testing Allegations for $6 Million ArentFox Schiff LLP
Apr
7
2023
Potential Nitrosamine Contamination Results in Another Voluntary Pharmaceutical Recall Nelson Mullins
Apr
7
2023
When Keeping Medication Safe May Lead to Increased Liability McDermott Will & Emery
Apr
7
2023
CMS Issues Medicare Drug Price Negotiation Initial Guidance, First Inflation Rebate List McDermott Will & Emery
Apr
7
2023
CMS Updates Could Help Employers on Second Round of Drug Cost Reporting Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Apr
6
2023
No Smoking Gun Here: Soliciting Input Sufficient to Satisfy Commission’s Statutory Obligation McDermott Will & Emery
Apr
6
2023
News Alert: Public Consultation on the EU’s Tobacco Products Legislation: Comment Period Open Until May 16, 2023 Keller and Heckman LLP
Apr
6
2023
DOC’s Bureau of Economic Analysis Releases Report on Developing a National Measure of the Economic Contributors of the Bioeconomy Bergeson & Campbell, P.C.
Apr
6
2023
FDA Announces First-Ever AI/ML Medical Device Draft Guidance Nelson Mullins
Apr
5
2023
D’Addario v. Johnson & Johnson – New Jersey Federal Court Addresses Express Pre-Emption In Class III Medical Device Case Sills Cummis & Gross P.C.
Apr
5
2023
“All Fruit” Jelly Label Continues to be Challenged in New York Federal Court Keller and Heckman LLP
Apr
5
2023
DOD Publishes Biomanufacturing Strategy and RFI on Biomanufactured Products and Process Capabilities Bergeson & Campbell, P.C.
Apr
4
2023
Is CMS Ignoring the Realities of Biopharmaceutical Costs? Epstein Becker & Green, P.C.
Apr
4
2023
COVID-19 Related Medical Devices: FDA Finalizes Transition Plan Guidance Foley & Lardner LLP
Apr
4
2023
Unpacking Averages: FDA FOIA Response Times by Topic of Request Epstein Becker & Green, P.C.
Apr
4
2023
Lawsuit Forces Early Release of NTP’s Draft Report on Fluoride, and its Potential Association with Neurodevelopment and Cognition ArentFox Schiff LLP
Apr
4
2023
White House Report Identifies Precision Medicine for Future R & D Investment Foley & Lardner LLP
Apr
4
2023
FDA Holds Joint Meeting on Food Safety with Mexican Counterparts Keller and Heckman LLP
Apr
3
2023
White House OSTP Outlines Goals for U.S. Biotechnology and Manufacturing Bergeson & Campbell, P.C.
Apr
3
2023
Editors’ Roundtable: Predictions About the Upcoming Farm Bill Bradley Arant Boult Cummings LLP
Apr
3
2023
FDA Publishes Framework for Digital Health Technologies in Clinical Trials Foley & Lardner LLP
Apr
3
2023
EPA Proposes National Primary Drinking Water Regulation to Set Stringent Limits on PFAS in Drinking Water, Including Four Newly Targeted Substances Hunton Andrews Kurth
Apr
3
2023
New Lawsuit Comes Amidst Push to Exclude Juice From “Healthy” Definition Keller and Heckman LLP
Mar
31
2023
McDermott+Consulting Check-Up: March 31, 2023 McDermott Will & Emery
Mar
31
2023
New Cosmetics Regulatory Scheme to Reshape Industry's Relationship with FDA McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins